Bioengineering (Dec 2022)

Stem Cell Therapy for Acute/Subacute Ischemic Stroke with a Focus on Intraarterial Stem Cell Transplantation: From Basic Research to Clinical Trials

  • Susumu Yamaguchi,
  • Michiharu Yoshida,
  • Nobutaka Horie,
  • Katsuya Satoh,
  • Yuutaka Fukuda,
  • Shunsuke Ishizaka,
  • Koki Ogawa,
  • Yoichi Morofuji,
  • Takeshi Hiu,
  • Tsuyoshi Izumo,
  • Shigeru Kawakami,
  • Noriyuki Nishida,
  • Takayuki Matsuo

DOI
https://doi.org/10.3390/bioengineering10010033
Journal volume & issue
Vol. 10, no. 1
p. 33

Abstract

Read online

Stem cell therapy for ischemic stroke holds great promise for the treatment of neurological impairment and has moved from the laboratory into early clinical trials. The mechanism of action of stem cell therapy includes the bystander effect and cell replacement. The bystander effect plays an important role in the acute to subacute phase, and cell replacement plays an important role in the subacute to chronic phase. Intraarterial (IA) transplantation is less invasive than intraparenchymal transplantation and can provide more cells in the affected brain region than intravenous transplantation. However, transplanted cell migration was reported to be insufficient, and few transplanted cells were retained in the brain for an extended period. Therefore, the bystander effect was considered the main mechanism of action of IA stem cell transplantation. In most clinical trials, IA transplantation was performed during the acute and subacute phases. Although clinical trials of IA transplantation demonstrated safety, they did not demonstrate satisfactory efficacy in improving patient outcomes. To increase efficacy, increased migration of transplanted cells and production of long surviving and effective stem cells would be crucial. Given the lack of knowledge on this subject, we review and summarize the mechanisms of action of transplanted stem cells and recent advancements in preclinical and clinical studies to provide information and guidance for further advancement of acute/subacute phase IA stem cell transplantation therapy for ischemic stroke.

Keywords